source
- FDA expands pirtobrutinib use to second-line CLL after covalent BTKi failure, broadening treatment optionsThe BRUIN CLL-321 phase 3 trial provided the data that led the FDA to approve pirtobrutinib for patients whose chronic lymphocytic leukemia has progressed after a covalent BTK inhibitor. This marks…
- Oral SERDs show promise in hormone-receptor positive breast cancer, offering alternative to injectionsOral selective estrogen receptor degraders (SERDs) are being positioned as a new approach for metastatic hormone-receptor positive breast cancer because they can break down the estrogen receptor an…